{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:53:40Z","timestamp":1791262420282,"version":"4.1.0"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The low-FODMAP diet is recommended by clinical guidelines as an effective dietary strategy for alleviating symptoms in patients with irritable bowel syndrome (IBS). However, its effect on\n                      <jats:italic>Bifidobacterium<\/jats:italic>\n                      and\n                      <jats:italic>Faecalibacterium prausnitzii<\/jats:italic>\n                      (\n                      <jats:italic>F. prausnitzii<\/jats:italic>\n                      ) remains unclear, largely due to methodological heterogeneity.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched the literature up to September 2026 for randomized controlled trials comparing low-FODMAP diets with control diets in adults with IBS. Given the high methodological heterogeneity across studies, we performed a direction-of-effect and consistency analysis (vote counting and sign test) instead of a traditional meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      12 RCTs were included. For\n                      <jats:italic>Bifidobacterium<\/jats:italic>\n                      (11 studies), 9 (81.8%) reported a decrease and 2 reported no change; the sign test confirmed a consistent reduction (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.033). A sensitivity analysis including only studies with direct between-group comparisons (9 studies) was consistent with the aforementioned analysis (8 reported a decrease,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.020). For\n                      <jats:italic>F. prausnitzii<\/jats:italic>\n                      (7 studies), the evidence was inconsistent: 2 reported a decrease, 4 reported no change, and 1 reported an increase, with no statistically significant trend.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Most current evidence indicates that a low FODMAP diet reduces the abundance of\n                      <jats:italic>Bifidobacterium<\/jats:italic>\n                      in IBS patients, while its effect on\n                      <jats:italic>F. prausnitzii<\/jats:italic>\n                      remains unclear. This finding enables clinicians to conduct more evidence-based counseling with patients, clarifying the specific effects (and non-effects) of the low-FODMAP diet on microbiota and facilitating informed decision-making regarding dietary management. Furthermore, future research should investigate the dynamics of microbiota during the reintroduction phase and consider patient microbiota subtypes to clarify the overall impact of the diet on the microbiota.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      This systematic review has been registered with PROSPERO (International Prospective Register of Systematic Reviews) under the registration number CRD420261351146. The publicly accessible URL is:\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2026.1948754","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:15Z","timestamp":1791260715000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evidence consistency analysis of the effect of a low-FODMAP diet on the abundance of Bifidobacterium and Faecalibacterium prausnitzii in patients with irritable bowel syndrome"],"prefix":"10.3389","volume":"17","author":[{"given":"Bingqian","family":"Cao","sequence":"first","affiliation":[{"name":"School of Public Health, Wuhan University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhou","sequence":"additional","affiliation":[{"name":"School of Public Health, Wuhan University of Science and Technology","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouzhang","family":"Hu","sequence":"additional","affiliation":[{"name":"Medical Imaging Department, Wuhan University of Science and Technology Hospital","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Huang","sequence":"additional","affiliation":[{"name":"Institute of Food Safety and Nutrition Hygiene, Wuhan Center for Disease Control and Prevention","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/s2468-1253(20)30056-x","article-title":"Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial","volume":"5","author":"Andresen","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e30291","DOI":"10.2196\/30291","article-title":"Long-term effects of a web-based low-FODMAP diet versus probiotic treatment for irritable bowel syndrome, including shotgun analyses of microbiota: randomized, double-crossover clinical trial","volume":"23","author":"Ankersen","year":"2021","journal-title":"J. Med. Internet Res."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.11124\/jbies-22-00430","article-title":"The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials","volume":"21","author":"Barker","year":"2023","journal-title":"JBI Evid. Synth."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1128\/aem.72.5.3593-3599.2006","article-title":"Two routes of metabolic cross-feeding betweenBifidobacterium adolescentisand butyrate-producing anaerobes from the human gut","volume":"72","author":"Belenguer","year":"2006","journal-title":"Appl. Environ. Microbiol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10151-018-1835-9","article-title":"Is a low FODMAP diet dangerous?","volume":"22","author":"Bellini","year":"2018","journal-title":"Tech. Coloproctol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1136\/gutjnl-2016-313128","article-title":"Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs","volume":"67","author":"Bennet","year":"2018","journal-title":"Gut"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.13241\/j.cnki.pmb.2018.22.022","article-title":"Treatment effect of low FODMAP diet on the diarrhea-predominant irritable bowel syndrome","volume":"18","author":"Bin","year":"2018","journal-title":"Prog. Mod. Biomed."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"e13201","DOI":"10.1111\/eci.13201","article-title":"Effects of Bifidobacterium longum BB536 and Lactobacillus rhamnosus HN001 in IBS patients","volume":"50","author":"Bonfrate","year":"2020","journal-title":"Eur. J. Clin. Investig."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jrsm.1458","article-title":"The effect direction plot revisited: application of the 2019 Cochrane handbook guidance on alternative synthesis methods","volume":"12","author":"Boon","year":"2021","journal-title":"Res. Synth. Methods"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"111657","DOI":"10.1016\/j.celrep.2022.111657","article-title":"Diet-induced modifications to human microbiome reshape colonic homeostasis in irritable bowel syndrome","volume":"41","author":"Bootz-Maoz","year":"2022","journal-title":"Cell Rep."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1053\/j.gastro.2021.12.248","article-title":"AGA clinical practice update on the role of diet in irritable bowel syndrome: expert review","volume":"162","author":"Chey","year":"2022","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e70072","DOI":"10.1111\/1750-3841.70072","article-title":"The effects of low FODMAP diet on gut microbiota regulation: a systematic review and meta-analysis","volume":"90","author":"Chu","year":"2025","journal-title":"J. Food Sci."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e2208168119","DOI":"10.1073\/pnas.2208168119","article-title":"Plant N-glycan breakdown by human gut bacteroides","volume":"119","author":"Crouch","year":"2022","journal-title":"PNAS"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/s2468-1253(16)30022-x","article-title":"Functional gastrointestinal disorders: what's new for Rome IV?","volume":"1","author":"Drossman","year":"2016","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref16","first-page":"237","article-title":"Rome III new standard for functional gastrointestinal disorders","volume":"15","author":"Drossman","year":"2006","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV\u2014functional GI disorders: disorders of gut-brain interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"7835","DOI":"10.1128\/aem.01296-06","article-title":"Cross-feeding between bifidobacterium longum bb536 and acetate-converting, butyrate-producing Colon Bacteria during growth on Oligofructose","volume":"72","author":"Falony","year":"2006","journal-title":"Appl. Environ. Microbiol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/s0140-6736(20)31548-8","article-title":"Irritable bowel syndrome","volume":"396","author":"Ford","year":"2020","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.3109\/21691401.2015.1111238","article-title":"Role of NLRP3 inflammasome in Bifidobacterium longum-regulated visceral hypersensitivity of postinfectious irritable bowel syndrome","volume":"44","author":"Gu","year":"2016","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1136\/gutjnl-2014-307264","article-title":"Diets that differ in their FODMAP content alter the colonic luminal microenvironment","volume":"64","author":"Halmos","year":"2015","journal-title":"Gut"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1053\/j.gastro.2013.09.046","article-title":"A diet low in FODMAPs reduces symptoms of irritable bowel syndrome","volume":"146","author":"Halmos","year":"2014","journal-title":"Gastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e12969","DOI":"10.1111\/nmo.12969","article-title":"Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome","volume":"29","author":"Hustoft","year":"2016","journal-title":"Neurogastroenterol. Motil."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s44247-024-00097-6","article-title":"Efficacy of digital interventions on physical activity promotion in individuals with noncommunicable diseases: an overview of systematic reviews","volume":"2","author":"Kardan","year":"2024","journal-title":"BMC Digit. Health"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG clinical guideline: management of irritable bowel syndrome","volume":"116","author":"Lacy","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev-med-050218-013625","article-title":"Low-FODMAP diet for irritable bowel syndrome: what we know and what we have yet to learn","volume":"71","author":"Liu","year":"2020","journal-title":"Annu. Rev. Med."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.dld.2017.01.142","article-title":"Altered molecular signature of intestinal microbiota in irritable bowel syndrome patients compared with healthy controls: a systematic review and meta-analysis","volume":"49","author":"Liu","year":"2017","journal-title":"Dig. Liver Dis."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2347715","DOI":"10.1080\/19490976.2024.2347715","article-title":"Metabolome-associated psychological comorbidities improvement in irritable bowel syndrome patients receiving a probiotic","volume":"16","author":"Martin","year":"2024","journal-title":"Gut Microbes"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1136\/gutjnl-2015-311339","article-title":"FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial","volume":"66","author":"McIntosh","year":"2017","journal-title":"Gut"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"15782","DOI":"10.1038\/srep15782","article-title":"Bifidobacteria exhibit social behavior through carbohydrate resource sharing in the gut","volume":"5","author":"Milani","year":"2015","journal-title":"Sci. Rep."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"e00300","DOI":"10.1128\/mBio.00300-15","article-title":"Identification of metabolic signatures linked to anti-inflammatory effects of Faecalibacterium prausnitzii","volume":"6","author":"Miquel","year":"2015","journal-title":"MBio"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"19399","DOI":"10.1038\/srep19399","article-title":"Anti-nociceptive effect of Faecalibacterium prausnitzii in non-inflammatory IBS-like models","volume":"6","author":"Miquel","year":"2016","journal-title":"Sci. Rep."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"Declaraci\u00f3n PRISMA 2020: una gu\u00eda actualizada para la publicaci\u00f3n de revisiones sistem\u00e1ticas","volume":"74","author":"Page","year":"2021","journal-title":"Rev. Esp. Cardiol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12263-010-0206-6","article-title":"Carbohydrate metabolism in Bifidobacteria","volume":"6","author":"Pokusaeva","year":"2011","journal-title":"Genes Nutr."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.jinf.2017.12.013","article-title":"Gut dysbiosis and irritable bowel syndrome: the potential role of probiotics","volume":"76","author":"Principi","year":"2018","journal-title":"J. Infect."},{"key":"ref37","first-page":"560","article-title":"Gut bacteria in health and disease","volume":"9","author":"Quigley","year":"2013","journal-title":"Gastroenterol. Hepatol."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2876","DOI":"10.1016\/j.cgh.2022.02.045","article-title":"Efficacy and acceptability of dietary therapies in non-constipated irritable bowel syndrome: a randomized trial of traditional dietary advice, the low FODMAP diet, and the gluten-free diet","volume":"20","author":"Rej","year":"2022","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1017\/s0007114510003363","article-title":"Prebiotic effects: metabolic and health benefits","volume":"104","author":"Roberfroid","year":"2010","journal-title":"Br. J. Nutr."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2545414","DOI":"10.1080\/19490976.2025.2545414","article-title":"Acute effects of butyrate on intestinal permeability in patients with irritable bowel syndrome assessed by a novel colonoscopy research model","volume":"17","author":"Scharf","year":"2025","journal-title":"Gut Microbes"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1093\/ajcn\/nqac176","article-title":"Effects of a low FODMAP diet on the colonic microbiome in irritable bowel syndrome: a systematic review with meta-analysis","volume":"116","author":"So","year":"2022","journal-title":"Am. J. Clin. Nutr."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"16731","DOI":"10.1073\/pnas.0804812105","article-title":"Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients","volume":"105","author":"Sokol","year":"2008","journal-title":"PNAS"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.3945\/jn.112.159285","article-title":"Fermentable carbohydrate restriction reduces luminal Bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome","volume":"142","author":"Staudacher","year":"2012","journal-title":"J. Nutr."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1053\/j.gastro.2017.06.010","article-title":"A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores Bifidobacterium species: a randomized controlled trial","volume":"153","author":"Staudacher","year":"2017","journal-title":"Gastroenterology"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1016\/s0016-5085(16)30842-3","article-title":"The low FODMAP diet reduces symptoms in irritable bowel syndrome compared with placebo diet and the microbiota alterations may be prevented by probiotic co-administration: a 2x2 factorial randomized controlled trial","volume":"150","author":"Staudacher","year":"2016","journal-title":"Gastroenterology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/j.clnu.2020.10.013","article-title":"Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probiotics","volume":"40","author":"Staudacher","year":"2021","journal-title":"Clin. Nutr."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"e14513","DOI":"10.1097\/md.0000000000014513","article-title":"Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome","volume":"98","author":"Sun","year":"2019","journal-title":"Medicine"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10620-017-4893-3","article-title":"Exploring gut microbiota composition as an Indicator of clinical response to dietary FODMAP restriction in patients with irritable bowel syndrome","volume":"63","author":"Valeur","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1007\/s00394-020-02473-0","article-title":"Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis","volume":"60","author":"van Lanen","year":"2021","journal-title":"Eur. J. Nutr."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1136\/gutjnl-2021-324598","article-title":"British Society of Gastroenterology guidelines on the management of irritable bowel syndrome","volume":"70","author":"Vasant","year":"2021","journal-title":"Gut"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1136\/gutjnl-2021-325177","article-title":"Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet","volume":"71","author":"Vervier","year":"2022","journal-title":"Gut"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.3389\/fmicb.2019.02407","article-title":"Rarefaction, alpha diversity, and statistics","volume":"10","author":"Willis","year":"2019","journal-title":"Front. Microbiol."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"906","DOI":"10.14309\/ajg.0000000000000641","article-title":"\u03b2-Galactooligosaccharide in conjunction with low FODMAP diet improves irritable bowel syndrome symptoms but reduces fecal Bifidobacteria","volume":"115","author":"Wilson","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"107190","DOI":"10.1016\/j.fbio.2025.107190","article-title":"A low-FODMAP diet enhances IBS symptom relief and gut microbiota homeostasis: a meta-analysis","volume":"71","author":"Yang","year":"2025","journal-title":"Food Biosci."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1093\/ajcn\/nqab005","article-title":"Low fermentable oligosaccharides, disaccharides, monosaccharides, and polyols diet compared with traditional dietary advice for diarrhea-predominant irritable bowel syndrome: a parallel-group, randomized controlled trial with analysis of clinical and microbiological factors associated with patient outcomes","volume":"113","author":"Zhang","year":"2021","journal-title":"Am. J. Clin. Nutr."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1782156","DOI":"10.1080\/19490976.2020.1782156","article-title":"Bifidobacterium longum alleviates irritable bowel syndrome-related visceral hypersensitivity and microbiota dysbiosis via Paneth cell regulation","volume":"12","author":"Zhou","year":"2020","journal-title":"Gut Microbes"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1948754\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:25:17Z","timestamp":1791260717000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1948754\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":56,"alternative-id":["10.3389\/fmicb.2026.1948754"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1948754","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1948754"}}